Abstract
In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
| Original language | English |
|---|---|
| Journal | Nature Reviews Clinical Oncology |
| DOIs | |
| Publication status | Accepted/In press - Jan 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Neuroendocrine neoplasia goes molecular — time for a change. / Rindi, Guido; Wiedenmann, Bertram.
In: Nature Reviews Clinical Oncology, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neuroendocrine neoplasia goes molecular — time for a change
AU - Rindi, Guido
AU - Wiedenmann, Bertram
PY - 2018/1/1
Y1 - 2018/1/1
N2 - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
AB - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
UR - http://www.scopus.com/inward/record.url?scp=85056124055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056124055&partnerID=8YFLogxK
U2 - 10.1038/s41571-018-0118-8
DO - 10.1038/s41571-018-0118-8
M3 - Article
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
SN - 1759-4774
ER -